Choroidal Rupture and Subretinal Hemorrhage

2022 ◽  
pp. 206-207
2017 ◽  
Vol 8 (1) ◽  
pp. 13-20 ◽  
Author(s):  
Shih Hao Wang ◽  
Chen Chee Lim ◽  
Yu Ti Teng

A case of choroidal rupture caused by airbag-associated blunt eye trauma and complicated with massive subretinal hemorrhage and vitreous hemorrhage that was successfully treated with intravitreal injection of expansile gas and bevacizumab is presented. A 53-year-old man suffered from loss of vision in his right eye due to blunt eye trauma by a safety airbag after a traffic accident. On initial examination, the patient had no light perception in his right eye. Dilated ophthalmoscopy revealed massive subretinal hemorrhage with macular invasion and faint vitreous hemorrhage. We performed intravitreal injection of pure sulfur hexafluoride twice for displacement, after which visual acuity improved to 0.03. For persistent subretinal hemorrhage and suspicion of choroidal neovascularization (CNV), intravitreal bevacizumab (1.25 mg/0.05 mL) injection was administered. After 3 weeks, the visual acuity of his right eye recovered to 0.4. For early-stage choroidal rupture-induced subretinal hemorrhage and complications of suspected CNV, intravitreal injection of expandable gas and intraocular injection of antiangiogenesis drugs seem to be an effective treatment.


Retina ◽  
1984 ◽  
Vol 4 (4) ◽  
pp. 269-275 ◽  
Author(s):  
JUAN P. AGUILAR ◽  
W RICHARD GREEN
Keyword(s):  

PLoS ONE ◽  
2013 ◽  
Vol 8 (1) ◽  
pp. e53338 ◽  
Author(s):  
Shoji Notomi ◽  
Toshio Hisatomi ◽  
Yusuke Murakami ◽  
Hiroto Terasaki ◽  
Shozo Sonoda ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Jae Hui Kim ◽  
Young Suk Chang ◽  
Jong Woo Kim ◽  
Chul Gu Kim ◽  
Dong Won Lee

Purpose. To investigate the incidence and timing of prechoroidal cleft development and its association with visual prognosis in type 3 neovascularization. Methods. This retrospective study included 166 eyes that were diagnosed with type 3 neovascularization. All eyes were treated with antivascular endothelial growth factor therapy. The incidence and timing of prechoroidal cleft development were evaluated. Best-corrected visual acuity (BCVA) at diagnosis and at final follow-up was compared between eyes with (cleft group) and without (no-cleft group) prechoroidal cleft. The incidence of retinal pigment epithelium (RPE) tear and subretinal hemorrhage was also compared between the two groups. Results. During the mean 39.7 ± 18.5 months of follow-up, prechoroidal cleft developed in 37 eyes (22.3%) at an average of 14.6 ± 10.4 months. The BCVA at final follow-up was significantly worse in the cleft group than in the no-cleft group (P=0.024), whereas the difference was not significant at diagnosis (P=0.969). The incidence of RPE tear (P=0.002) and subretinal hemorrhage (P<0.001) was significantly higher in the cleft group. Conclusions. Prechoroidal cleft is a frequently observed finding during the treatment course of type 3 neovascularization. Eyes with prechoroidal cleft are at high risk of RPE tear or subretinal hemorrhage and subsequently associated with poor prognosis.


2013 ◽  
pp. 351-352
Author(s):  
Roger P. Harrie ◽  
Cynthia J. Kendall

Sign in / Sign up

Export Citation Format

Share Document